Cytomegalovirus Vaccines: Current Status and Future Prospects

Research output: Contribution to journalReview articlepeer-review

74 Scopus citations


Congenital human cytomegalovirus (HCMV) infection can result in severe and permanent neurological injury in newborns, and vaccine development is accordingly a major public health priority. HCMV can also cause disease in solid organ transplant (SOT) and hematopoietic stem-cell transplant (HSCT) recipients, and a vaccine would be valuable in prevention of viremia and end-organ disease in these populations. Currently there is no licensed HCMV vaccine, but progress toward this goal has been made in recent clinical trials. A recombinant HCMV glycoprotein B (gB) vaccine has been shown to have some efficacy in prevention of infection in young women and adolescents, and has provided benefit to HCMV-seronegative SOT recipients. Similarly, DNA vaccines based on gB and the immunodominant T-cell target, pp65 (ppUL83), have been shown to reduce viremia in HSCT patients. This review provides an overview of HCMV vaccine candidates in various stages of development, as well as an update on the current status of ongoing clinical trials. Protective correlates of vaccine-induced immunity may be different for pregnant woman and transplant patients. As more knowledge emerges about correlates of protection, the ultimate licensure of HCMV vaccines may reflect the uniqueness of the target populations being immunized.

Original languageEnglish (US)
Pages (from-to)1625-1645
Number of pages21
Issue number17
StatePublished - Nov 1 2016

Bibliographical note

Funding Information:
Funding support from NIH awards HD044864, HD079918, AI114013 and HD082273 (to M.R.S.) and DE022732 (supporting C.J.B.) is acknowledged.

Publisher Copyright:
© 2016, Springer International Publishing Switzerland.


Dive into the research topics of 'Cytomegalovirus Vaccines: Current Status and Future Prospects'. Together they form a unique fingerprint.

Cite this